The ITF meeting represented a critical milestone at the midway of the Horizon 2020 project and accordingly the discussion with the EMA was long, intense and extremely fruitful. Conclusions and opinions of the meeting served to highlight both the complications of the field and legislation in general and the ambition and healthy state of the project as it enters a critical phase.
ELASTISLET is now heading into the final half of the project and the lead up to future clinical testing. The outcome of the meeting now paves the way for a final, defined approach to developing a clinic-ready product.
Since June 2015, Asphalion is cooperating with the other members of the consortium on a cross-disciplinary strategy and a unique objective: to develop a smarter strategy to cope with diabetes.
